ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2026
[Metformin Inhibits Prostate Cancer Progression via Regulation of the AKT/mTOR Signaling Pathway].
Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the effects of metformin on the proliferation, migration, and invasion of prostate cancer cells, and to determine whether its antitumor effects are mediated by regulation of human antigen R (HuR) and the AKT/mammalian target of rapamycin (mTOR) signaling pathway. Methods: Human prostate cancer cell lines PC3 and 22RV1 were used as the research models and were treated with metformin. HuR knockdown and overexpression experiments were performed to further verify the underlying mechanism. Cell proliferation was assessed using the cell counting kit-8 (CCK-8) assay. Cell migration and invasion were evaluated by Transwell assays. The expression levels of HuR and AKT/mTOR pathway-related proteins were measured by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting. Results: Metformin treatment reduced the proliferation, migration, and invasion abilities of PC3 and 22RV1 cells, and inhibited the expression of proteins associated with the AKT/mTOR signaling pathway ( Conclusion: Metformin may inhibit the activation of the AKT/mTOR signaling pathway by downregulating HuR expression, thereby reducing the proliferation, migration, and invasion of prostate cancer cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.